PMID

Data

Article Title

Organization

Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases.

Pfizer

Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction.

Astrazeneca

Small molecule and macrocyclic pyrazole derived inhibitors of myeloperoxidase (MPO).

Bristol-Myers Squibb

Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase.

Bristol Myers Squibb

Discovery of a novel indole pharmacophore for the irreversible inhibition of myeloperoxidase (MPO).

Novartis Institutes For Biomedical Research

Potent Triazolopyridine Myeloperoxidase Inhibitors.

Bristol-Myers Squibb Research and Development

Identification of a small molecule beta-secretase inhibitor that binds without catalytic aspartate engagement.

Merck Research Laboratories